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Abstract
In the past few years considerable advances have been made in
the genetics of susceptibility to rheumatoid arthritis (RA). For
decades the HLA-DRB1 alleles were the only extensively replica-
ted genetic factor, but more genetic risk factors have now been
identified that predispose to RA. Interestingly, several of the
observed genetic variants conferred risk to anticitrulline-peptide
antibody (ACPA)-positive RA and two variants may be restricted to
ACPA-negative RA, pointing to the need for subclassification of
RA. The current manuscript reviews recently identified genetic
factors predisposing to ACPA-positive RA and ACPA-negative RA.
Additionally, although being scarcely explored, genetic variants
affecting the severity of disease course are discussed.
Introduction
Rheumatoid arthritis (RA) is a chronic potentially destructive
arthritis classified by the presence of four out of the seven
criteria developed by the American College of Rheumatology
(ACR) in 1987. The criteria were formulated by experts who
compared characteristics of patients with longstanding
classical RA (mean disease duration 8 years). These ACR
criteria have been criticized during past years as they have a
low discriminative ability in patients presenting with recent-
onset arthritis [1-4]. This is not surprising considering the
components of the ACR criteria. One of the criteria is the
presence of erosions on the radiographs of hands and wrists.
In the early phases of RA only 13% of the patients have
erosive disease [5]. Additionally, erosions often initially
present in the small joints of the feet, and appear in the small
joints of the hands at a later point in the disease course [6].
Also, rheumatoid nodules are very rare in the early phases of
RA, and rheumatoid factor is present in only 50% of the
patients with early RA [7].
Conversely, the serological factor that has the strongest
association with RA, anticitrulline-peptide antibody (ACPA), is
not part of the classification criteria. A taskforce has therefore
been formed by the European League Against Rheumatism to
develop classification criteria for early inflammatory arthritis.
This taskforce is guided by the European League Against
Rheumatism Standing Committee on Epidemiology as well as
the ACR Quality Measurement Committee. It was agreed that
this was an appropriate goal and that a proposal outlining the
work to be done should be submitted to the Executive Board
of the European League Against Rheumatism and the ACR
for consideration of support. This exercise should not be seen
as an attempt to redefine criteria for established RA (as
classifiable by the original 1987 ACR criteria), but as an
attempt to develop criteria for early (actual or potential) RA.
Considering the classification of RA, several questions can
be raised. Do we consider RA one disease or is it a disorder
composed of several (sub)entities? Second, should classifi-
cation be based on clinical features or also on pathophysio-
logical characteristics? These questions are pressing, as
current evidence indicates that the identified genetic risk
factors do not predispose to all RA patients but only to a
specific subset.
The present manuscript highlights the latest advances in the
genetics of RA susceptibility in relation to subdivision of the
disease based on autoantibodies, in particular ACPA. The
genetic risk factors that predispose to ACPA-positive RA and
ACPA-negative RA are reviewed. Additionally, the current
knowledge on genetic variants involved in the severity of RA
is evaluated.
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Genetic factors predisposing to
anticitrulline-peptide antibody-positive RA
Human leucocyte antigens class II
The most important genetic risk factor for RA was identified
three decades ago and consists of the human leucocyte
antigen (HLA) class II molecules. There is extensive evidence
showing that certain frequently occurring HLA-DRB1 alleles
(HLA-DRB1*0101, HLA-DRB1*0102, HLA-DRB1*0401,
HLA-DRB1*0404, HLA-DRB1*0405, HLA-DRB1*0408,
HLA-DRB1*0410 HLA-DRB1*1001, HLA-DRB1*1402) are
associated with susceptibility to RA. The indicated alleles
share a conserved amino acid sequence (QKRAA, QRRAA or
RRRAA) – also called the shared epitope (SE) – at position
70 to 74 in the third hypervariable region of the DRβ1 chain.
These residues are part of an α-helical domain forming one
side of the antigen-presenting binding site.
The SE hypothesis postulates that the SE motif itself is
directly involved in the pathogenesis of RA by allowing the
presentation of a peptide to arthritogenic T cells [8]. No
specific arthritogenic peptides that bind to the HLA-DRB1
proteins and subsequently activate T cells have so far been
identified, hence the SE hypothesis is not functionally proven.
Nevertheless, this hypothesis is robust because of its consis-
tent association (although quantitatively varying between
alleles and populations) among various ethnic populations. It
is estimated that the heritability of susceptibility to RA is 50%
to 60% and that the SE alleles account for at least 30% of
the total genetic effect [9,10].
The role of the HLA-DRB1 SE alleles as well as of ACPA in
RA susceptibility was recently studied in greater depth, and
it was observed that the SE alleles associate only with RA
patients who carry ACPA and not with ACPA-negative RA
patients [11,12]. This finding led to the hypothesis that the
SE alleles confer risk to ACPA rather than to (ACPA-
positive) RA. To investigate this hypothesis, the progression
from recent-onset undifferentiated arthritis to RA was
studied in relation to the SE alleles and autoantibodies
[11,13]. In patients who presented with undifferentiated
arthritis, the presence of ACPA was associated with
progression to RA, both in SE-positive undifferentiated
arthritis patients and in SE-negative undifferentiated arthritis
patients. In contrast, both in ACPA-positive undifferentiated
arthritis patients and ACPA-negative undifferentiated arthritis
patients, the association between the SE alleles and the
development of RA was lost, indicating that the predictive
value of the SE alleles is lost once the ACPA response has
developed [12]. These data indicate that the SE alleles
particularly confer risk to ACPA and that these antibodies
explain the association between the SE alleles and RA.
Moreover, these observations provided the first evidence
that the etiopathology of ACPA-positive RA is different from
that of ACPA-negative RA.
Protein tyrosine phosphatase nonreceptor 22
The second risk factor for RA, identified in 2004, is non-HLA
linked and concerns the C1858T single nucleotide poly-
morphism (SNP) in the gene encoding for the protein tyrosine
phosphatase nonreceptor 22 (PTPN22) [14]. An association
between PTPN22 and RA has presently been demonstrated
in several populations [15-17], and several studies have
revealed that the PTPN22 T allele not only confers risk to RA
but also to other autoimmune diseases such as lupus, type 1
diabetes and Graves disease. Intriguingly, PTPN22 is
associated with ACPA-positive RA but not with ACPA-
negative RA [17]. Moreover, in three independent cohorts of
RA patients a gene–gene interaction for the HLA SE alleles
and PTPN22 was shown for ACPA-positive RA, but not for
ACPA-negative RA [18]. This observation strengthens the
assumption that ACPA-positive RA and ACPA-negative RA
have a different pathogenesis.
PTPN22 encodes for a lymphoid tyrosine phosphatase that
affects the threshold for T-cell receptor signaling through
binding to a Csk kinase. In vitro experiments have shown that
the PTPN22 T-allele-encoded protein binds less efficiently to
Csk, suggesting that the T cells expressing the T allele are
hyperresponsive [14]. Knocking out the murine homologue of
PTPN22 resulted in lower thresholds of T-cell activation and
induced an increased expansion and function of the effector/
memory T-cell pool, which was associated with elevated
levels of serum antibodies [19]. Both of these studies
indicate that the PTPN22 risk allele is associated with a
reduced downregulation of T-cell activation. In contrast to this
loss of function, a gain of function has also been described in
carriers of the PTPN22 T allele [20]. Hence the biological
mechanisms underlying the association between PTPN22
and RA are incompletely understood.
Complement component 5-TNF receptor-associated
factor 1
Only very recently was the third genetic risk factor for RA
identified. Interestingly, the observation was made in three
countries at the same time using different approaches. In a
study performed in the Netherlands, a candidate-gene
approach showed an association between RA susceptibility
and complement component 5-TNF receptor-associated
factor 1 (C5-TRAF1) [21]. In this study the complement C5
region on chromosome 9q33–34 was investigated as a
candidate because mice studies revealed that mice deficient
in complement factors are resistant to arthritis and that
targeting C5 by antibodies prevents the onset of arthritis and
reduces the clinical severity of arthritis in mice [22,23]. Other
studies showed that C5a receptor-deficient mice are
resistant to arthritis induction [24]. These data combined with
the observation that high levels of C5a are found in synovial
fluid of RA patients suggested these mediators play a central
role in arthritis [25]. Investigating the SNPs spanning this
region revealed significant associations; the most significant
SNP was not located within C5 but between C5 and TRAF1Page 3 of 8
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[21]. The protein encoded by TRAF1 is a member of the TNF
receptor-associated factor 1 protein family, which mediates
the signal transduction from various receptors of the TNF
receptor superfamily, including the receptor for TNFα.
Interestingly, as this candidate gene study was completed an
association between the C5-TRAF1 region was also demon-
strated in two independent genome-wide association studies
in the USA and Sweden [26]. The demonstration of similar
results in independent studies making use of different
approaches provides strong evidence for the C5-TRAF1
region as a true RA-associated genetic variant. Moreover,
additional evaluation in the Dutch study revealed that this
genetic risk factor specifically predisposes to ACPA-positive
RA and not to ACPA-negative RA [21]. The two genome-
wide association studies showing an association between
C5-TRAF1 and RA only investigated ACPA-positive patients
[26].
At present it is not clear whether the most significant SNP in
C5-TRAF1 is causative since other proxies in high-linkage
disequilibrium with this SNP can also be responsible for the
observed association. Additionally, the functional conse-
quence of carrying the C5-TRAF1 polymorphism is as yet
unknown.
Cytotoxic T lymphocyte antigen 4
A genetic risk factor that has been investigated frequently in
relation to RA, providing inconsistent results, is a noncoding
variant in the 3′ end of the gene encoding for cytotoxic
T lymphocyte antigen 4 (CTLA4) [27,28]. Combined data
from the USA and Sweden have more recently suggested
that CTLA4 confers risk only to the subset of ACPA-positive
RA patients and not to ACPA-negative disease [29]. This
association, however, was only found in the Swedish cohort
and not in the American cohort. Although this may be seen as
support for another genetic risk factor that mainly contributes
to ACPA-positive disease, it may also be a false-positive
finding or a population-specific effect.
The CTLA4 protein plays an important role in downregulation
of T-cell activation. To be fully activated the T cell requires the
recognition of an antigen bound to HLA and a costimulatory
signal between CD80 or CD86 on the antigen-presenting
cell and CD28 on the T cell. This costimulatory signal can be
inhibited by CTLA4, which is expressed on T cells as CTLA4
binds to CD80/CD86 with higher affinity.
STAT4
Very recently, a linkage peak on the long arm of chromosome
2 was investigated thoroughly. The study confirmed the
association between CTLA4 and RA but also observed an
association with an unlinked SNP in the region encoding for
STAT4 [30]. This finding was observed in a Swedish as well
as an American case–control study. Although the majority of
the RA patients of the American cohort were ACPA-positive,
such data on the Swedish cohort were not provided. Based
on this study, therefore, no information is available on whether
STAT4 predisposes to ACPA-positive RA and/or ACPA-
negative RA. Additionally, it cannot be excluded that this
study provided false-positive results. Multiple replication
studies are thus required before this polymorphism can be
added to the list of identified risk factors for RA.
TNFα α-induced protein 3-oligodendrocyte lineage
transcription factor 3 (TNFAIP3-OLIG3)
The Wellcome Trust Case Control Consortium performed a
genome-wide association study in almost 2,000 RA patients.
They reported moderately associated regions on chromo-
some 6 (6q23) located between the genes encoding for
TNFAIP3-OLIG3, which were unequivocally replicated in a
follow-up study [31]. In total, combining the Wellcome Trust
Case Control Consortium data with the validation cohort,
2,515 ACPA-positive RA patients and 1,039 ACPA-negative
RA patients were compared with 6,629 healthy control
individuals, revealing only significant results in the ACPA-
positive patients [31].
Another SNP, located 3.8 kb from the abovementioned SNP,
was found by an independent group that evaluated only
ACPA-positive patients. The effects of this SNP on suscepti-
bility to RA were reported to be statistically independent from
the SNP initially described by the Wellcome Trust Case
Control Consortium [32]. Although the function of these
intergenic SNPs as well as the definite haplotypes that
predispose or protect to RA are not fully elucidated, these
data do suggest that the gene(s) in the region encoding for
TNFAIP3-OLIG3 are of importance for susceptibility to
ACPA-positive RA.
Fc-receptor-like gene 3
A functional promoter polymorphism (–169T → T) in the Fc-
receptor-like gene 3 at chromosome 1q21–23 was first
demonstrated to be associated with RA in two independent
Japanese case–control studies [33,34]. Subsequently a
number of studies evaluated this polymorphism, showing
contrasting results. Two meta-analyses revealed recently that
this SNP has a role in the risk for RA amongst East Asians,
but there is no compelling evidence for an association of this
SNP with RA in Caucasians [35,36]. Similarly, although
Kochi and colleagues suggested this SNP influences the
level of autoantibodies, a recent study from Norway found no
association between the Fc-receptor-like gene 3 genotype
and the level of ACPA [37]. These data demonstrate that
associations between genetic variants and disease may differ
in diverse ethnic populations.
Peptidylarginine deiminase 4
Another genetic variant, the potency of which differs between
populations, is peptidylarginine deiminase 4 (PADI4). Large-
scale linkage disequilibrium studies and subsequent
replication studies implicated a variant of PADI4 as a risk
Available online http://arthritis-research.com/content/10/2/205factor for RA in Japanese and Korean populations [38,39].
This finding that was not observed in the majority of studies in
populations of European descent. Intriguingly, the Japanese/
Korean association is with a haplotype rather than with a SNP
with a proposed function. Another SNP linked to this
haplotype may therefore be the causative risk factor.
Interestingly, a German study revealed an association
between  PADI4 and RA but the haplotypes providing this
association were different to the haplotypes that conferred
risk in the Asian populations [40]. This may indicate that
PADI4 or a factor linked to PADI4 may predispose to RA but
that the actual causing genetic variant is not elucidated.
Possible other explanations for this discrepancy are the
presence of other genetic or environmental factors that inter-
act with the genetic factor in a specific population, thereby
affecting disease susceptibility or enrichment of genetic
variants in one population but not in the other population.
Although the peptidylarginine deiminases are implicated in
the generation of ACPA, there is no compelling evidence
supporting PADI4 genotypes correlating with ACPA levels –
or ACPA-positive disease in particular.
Genetic factors predisposing to
anticitrulline-peptide antibody-negative RA
Human leucocyte antigens class II
The assumption that the etiopathology of ACPA-positive RA
is different from that of ACPA-negative RA is strengthened
when genetic risk factors are found that exclusively associate
with RA characterized by the absence of ACPA. Two
independent studies showed that the HLA-DR3 alleles
predispose only to ACPA-negative RA but not to ACPA-
positive RA [12,41]. Whether this association is attributable
to the HLA-DR3 gene itself or to genes linked to this locus is
not known, however, as HLA-DR3 is part of a conserved
ancestral haplotype (A1;B8;DRB1*03). The major histo-
compatibility complex class III region – encoding for, amongst
others, TNF and lymphotoxin α – is also part of this ancestral
haplotype and has been described to influence the
susceptibility to RA.
Nonhuman leucocyte antigens
Recently described in a Swedish cohort and a Dutch cohort
of patients was a second risk factor for ACPA-negative RA –
interferon regulatory factor 5 (IRF5) [42]. Whereas IRF5 is
consistently associated with susceptibility to lupus, the
correlation of IRF5  with RA is less clear as French and
Spanish studies observed no association between IRF5 and
RA [43,44]. Nevertheless these two studies did not
investigate the effect of this risk factor on ACPA-negative RA
separately, and thus these findings may be false negative.
Future studies may further increase comprehension of the
role of IRF5 in RA.
The fact that more genetic risk factors for ACPA-positive
disease have thus far been identified than for ACPA-negative
RA does not necessarily indicate that the contribution of
genetic factors to the etiopathology of ACPA-positive RA is
larger than that to the etiopathology of ACPA-negative RA. In
contrast, many important studies that revealed new genetic
risk factors used cohorts constituting of mainly ACPA-
positive RA patients [14,30-32]. Part of the research
conducted is thus biased towards locating genetic variants
predisposing to ACPA-positive RA.
Pathophysiological differences between
anticitrulline-peptide antibody-positive RA and
anticitrulline-peptide antibody-negative RA
The reports demonstrating dissimilar genetic risk factors for
ACPA-positive RA and ACPA-negative RA strongly suggest
that ACPA-positive RA and ACPA-negative RA are separate
subsets of RA with pathophysiological differences.
Nonetheless, the effects of the described polymorphisms on
gene function are still uncertain. Although the first structural
difference between ACPA-positive RA and ACPA-negative
RA – a difference in synovial tissue infiltrates between ACPA-
positive RA patients and ACPA-negative RA-patients with
active arthritis – was recently observed [45], the complete
spectrum of pathophysiologic differences between ACPA-
positive RA and ACPA-negative RA is as yet incompletely
identified.
Recent advances in the genetics of RA severity
Altogether the genetics of RA susceptibility has made
enormous progress during the past years, several more
genetic risk factors will be recognized – considering the
enormous efforts that are currently being made for RA
susceptibility. In contrast, the field of the genetics of RA
severity is relatively unexplored. Radiological joint damage is
conceived as the most objective measure to determine the
severity of RA. The number of studies investigating the
relation between joint destruction and genetic variants is
limited. Some SNPs are observed to associate with the
disease outcome, but none of these associations are
convincingly replicated in independent cohorts. Moreover,
although a recent twin study indicated that genetic factors
play a role in determining the severity of RA [46], the
heritability of the level of joint destruction (the variance of joint
destruction that can be ascribed to genetic factors) is still
unknown.
Joint damage in RA is highly variable between patients and
the cumulative level is associated with the level of (persistent)
inflammation. Nonetheless, several studies have provided
evidence for incomplete coupling between inflammation and
destruction, which suggests that other individual factors also
play a role. This suggestion leads to the hypothesis that
candidate genes for the severity of RA are, on the one hand,
genes that regulate the level of (local) inflammation and, on
the other, genes that mediate the process of bone/cartilage
destruction or bone regeneration. The contemporary data on
genetics of RA severity are summarized below.
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The HLA-SE alleles, and the DR4 alleles in particular, are
known to predispose to a destructive disease course. It is
now also known that the SE alleles primarily associate with
the presence of ACPA and that these autoantibodies are a
strong predictor for a severe disease outcome. This
knowledge results in the question of whether the SE alleles
contribute to a destructive disease course independent of the
disease’s effect on ACPA; a question that remains unsolved.
The HLA-DRB1 alleles not only encode for risk factors but
are also protective factors. The HLA-DRB1 alleles encoding
for the amino acids DERAA protect against a destructive
disease course, an effect that is independent of the
presence/absence of SE alleles but is most evident in the
ACPA-positive group [47].
Genetic variants in interleukins
Within a number of cytokines such as TNFα, IL1, IL4, IL-1α,
IL-1β or IL-1RN, variations have been reported and associa-
tions have been found only in small studies that are not
independently replicated [48-50]. Future studies will reveal
whether the observed associations will be observed in
replication studies.
Genetic variants in complement components
The SNPs located in the region encoding for C5 and TRAF1
observed to associate with susceptibility to RA in three
different cohorts [21,26] were evaluated for their correlation
with disease severity in one study [21]. This provided the first
indication that carrying the C5-TRAF1 risk allele relates to a
destructive disease course. This association is not yet
replicated, however, and it has not been investigated whether
the correlation with a severe disease course was indepen-
dent of ACPA.
Genetic variants in mediators of bone/cartilage
destruction
The destruction of bone and cartilage in RA is mediated by
proteolytic enzymes that belong to the family of matrix
metalloproteinases (MMPs). The most intensively studied
proteinases are MMP3 (stromelysin) and MMP1 (collage-
nase). The levels of these MMPs are increased in both serum
and synovial fluid of patients with RA, and the serum levels of
MMP3 have been correlated with joint destruction in RA.
Studies assessing polymorphism within the MMP3 gene
promoter region revealed correlations between MMP3
haplotypes and joint damage; however, the results on which
haplotypes conferred an increased risk were inconsistent
[51-53]. Further evaluation of the effect of genetic variation in
MMP3 on the level of joint damage in RA is therefore
required.
The increasing comprehension of the role of genetics in
disease outcome in RA may promote the development of
personalized medicine. Although the prospects of RA
patients on a group level have improved dramatically due to
the growing arsenal of new aggressive antirheumatic drugs
and recent data demonstrating that combination therapy is
more effective than monotherapy, these developments do not
automatically lead to benefit on the individual level. At
present, >95% of newly diagnosed RA patients start with
methotrexate monotherapy, which is ineffective in 66% of
patients [54]. Subsequently, methotrexate is switched to
another disease-modifying antoretroviral drug or a disease-
modifying antoretroviral drug is added to the methotrexate
therapy; if this strategy also fails, targeted therapies such as
TNF blockers may be prescribed. The disease course in RA is
highly variable and this commonly used step-up therapeutic
strategy implies that a proportion of newly diagnosed RA
patients are insufficiently treated for a specific time, resulting
in the development of erosions that might have been
prevented if a more vigorous treatment strategy had been
applied. Clinical and serological characteristics solely are
insufficient to predict the disease outcome in individual
patients [55]. Additional knowledge on genetic variants will
increase the predictive ability.
Conclusion
Several genetic factors are associated with susceptibility to
RA. Interestingly, the majority of the identified genetic factors
conferred risk to ACPA-positive RA, whereas two genetic
Available online http://arthritis-research.com/content/10/2/205
Page 5 of 8
(page number not for citation purposes)
Table 1
Genetic factors confirmed for or suggestive of association with anticitrulline-peptide antibody (ACPA)-positive and ACPA-negative
rheumatoid arthritis
Factor ACPA-positive rheumatoid arthritis ACPA-negative rheumatoid arthritis
Confirmed Human leucocyte antigen shared epitope alleles Human leucocyte antigen DR3
Protein tyrosine phosphatase nonreceptor 22 (PTPN22)
Complement component 5-TNF receptor-associated factor 1 (C5-TRAF1)
TNFα-induced protein 3-oligodendrocyte lineage transcription factor 3 (TNFAIP3-OLIG3)
Suggestive Cytotoxic T lymphocyte antigen 4 (CTLA4) Interferon regulatory factor 5 (IRF5)
Signal transducer and activator of transcription 4 (STAT4)variants may be restricted to ACPA-negative RA (Table 1).
This observation illustrates that knowledge of genetic variants
may contribute to the understanding of RA and that sub-
classification of RA into ACPA-positive and ACPA-negative
entities is advocated. Nonetheless, the complete spectrum of
pathophysiologic differences between ACPA-positive RA and
ACPA-negative RA is incompletely identified and the effects
of the described polymorphisms on gene function are still
uncertain. Further studies elucidating these effects will
enhance the understanding of the mechanisms of disease
and will thereby promote the development of targeted
therapies and the translation from genetics to clinical
practice.
In contrast to the recent advances in the field of susceptibility
to RA, genetic variants affecting the severity of the disease
course in RA are scarcely explored. It is hoped that future
studies will identify genetic risk factors that predict a severe
disease course and that these result will allow personalized
medicine in RA, thereby reducing avoidable joint destruction
due to undertreatment and also lessening complications due
to overtreatment.
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